Skip to main content
. 2021 Jul 16;13(14):3569. doi: 10.3390/cancers13143569

Table 2.

Number of patients in each category.

Amplified Not amplified Not available
EGFR 31 (72.09%) 12 (27.9%) 0 (0%)
Unmethylated Methylated Not available
MGMT 24 (55.8%) 18 (41.8%) 1 (2.3%)
MGMT unmethylated, EGFR amplified 17 (40.4%)
MGMT methylated, EGFR amplified 13 (30.9%)
MGMT unmethylated, EGFR not amplified 7 (16.6%)
MGMT methylated, EGFR not amplified 5 (11.9%)